Dennis J. Dlugos, MD, MSCE
Professor of Neurology at the Children's Hospital of Philadelphia
Director, Pediatric Epilepsy Program, Division of Neurology, The Children's Hospital of Philadelphia
Associate Dean for UME Science and Discovery Curriculum, Perelman School of Medicine at the University of Pennsylvania
Department: Neurology
Contact information
Division of Neurology
Children's Hospital of Philadelphia
34th and Civic Center Blvd
Colket Translational Research Building
1st floor, Room 1200.14
Philadelphia, PA 19104
Children's Hospital of Philadelphia
34th and Civic Center Blvd
Colket Translational Research Building
1st floor, Room 1200.14
Philadelphia, PA 19104
Office: 215-590-1719
Fax: 215-590-2950
Fax: 215-590-2950
Email:
dlugos@email.chop.edu
dlugos@email.chop.edu
Education:
B.A. (Theology)
Loyola Marymount University, Los Angeles, CA, 1983.
M.D. (Medicine)
Columbia University College of Physicians & Surgeons, New York, NY, 1988.
M.S.C.E (Clinical Epidemiology)
Master’s of Science in Clinical Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, 2002.
Permanent linkB.A. (Theology)
Loyola Marymount University, Los Angeles, CA, 1983.
M.D. (Medicine)
Columbia University College of Physicians & Surgeons, New York, NY, 1988.
M.S.C.E (Clinical Epidemiology)
Master’s of Science in Clinical Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, 2002.
Description of Research Expertise
Epilepsy EpidemiologyEpilepsy Genetics
Clinical Prediction Models
Description of Clinical Expertise
Pediatric EpilepsyEpilepsy Genetics
Epilepsy Surgery
EEG
Clinical Neurophysiology
Selected Publications
Buchhalter J, Neuray C, Cheng J, D’Cruz O, Datta A, Dlugos D, French J, Haubenberger D, Hulihan J, Klein P, Komorowski R, Kramer L, Lothe A, Nabbout R, Perucca E, Van der Ark P: EEG parameters as endpoints in epilepsy clinical trials - An expert panel opinion paper. Epilepsy Research 187: 107028, Nov 2022.Sperling MR, Wheless J, Hogan RE, Dlugos D, Cascino G, Liow K, Rabinowicz A, Carrazana E: Use of Second Doses of Diazepam Nasal Spray Across 24 Hours After the Initial Dose for Out-of-Hospital Seizure Clusters: Results From a Phase 3, Open-Label, Repeat-Dose Safety Study. Epilepsia 63: 836-843, 2022.
Tarquinio D, Dlugos D, Wheless JW, Desai J, Carrazana E, Rabinowicz AL: Safety of Diazepam Nasal Spray in Children and Adolescents With Epilepsy: Results From a Long-Term Phase 3 Safety Study. Pediatric Neurology 132: 50-55, 2022.
Hahn CD, Jiang Y, Villanueva V, Zolnowska M, Arkilo5 D, Hsiao S, Asgharnejad M, Dlugos D: A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox–Gastaut syndrome (ELEKTRA). Epilepsia 63: 2671-2683, 2022.
Knupp KG, Coryell J, Singh RK, Gaillard W, Shellhaas R, Koh S, Mitchell WG, Harini C, Millichap JJ, May A, Dlugos D, Nickels K, Mytinger JR, Keator C, Yozawitz E, Singhal N, Lockrow J, Thomas JF, Juarez-Colunga E: Comparison of cosyntropin, vigabatrin and combination therapy in new onset infantile spasms in a prospective randomized trial. Journal of Child Neurology 37: 186-193, 2022.
Koko M, Motelow JE, Stanley KE, Bobbili DR, Dhindsa RS, May P, Canadian Epilepsy Network, Epi4K Consortium, Epilepsy Phenome/Genome Project (including Dlugos D), EpiPGX Consortium, EuroEPINOMICS-CoGIE Consortium: Association of ultra-rare coding variants with genetic generalized epilepsy: a case control whole exome sequencing study Epilepsia 63: 723-735, 2022.
Wheless JW, Miller I, Hogan RE, Dlugos D, Biton V, Cascino GD for the DIAZ.001.05 Study Group: Final results from a phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy. Epilepsia 62: 2485-2495, 2021.
Millichap JJ, Harden CL, Dlugos DJ, French JA, Butterfield NH, Grayson C, Aycardi E, Pimstone SN: Capturing seizures in clinical trials of anti-seizure medications for KCNQ2 DEE. Epilepsia Open 6: 38-44, 2021.
Miller I, Wheless JW, Hogan RE, Dlugos D, Biton V, Cascino GD, Sperling MR, Liow K, Vazquez B, Segal EB, Tarquinio D, Mauney W, Desai J, Rabinowicz AL, Carrazana E, for the DIAZ.001.05 Study Group : Consistent Safety and Tolerability of Diazepam Nasal Spray in Relationship to Usage Frequency in Patients With Seizure Clusters: Interim Results From A Phase 3, Long-Term, Open-Label, Repeat-Dose Safety Study. Epilepsia Open 6: 504-512, 2021.
Segal EB, Tarquinio D, Miller I, Wheless JW, Dlugos D, Biton V, Cascino GD, Desai J, Hogan RE, Liow K, Sperling MR, Vazquez B, Cook DF, Rabinowicz AL, Carrazana E, for the DIAZ.001.05 Study Group: Evaluation of Diazepam Nasal Spray in Patients with Epilepsy Concomitantly Using Maintenance Benzodiazepines: An Interim Subgroup Analysis from a Phase 3, Long-term, Open-label Safety Study. Epilepsia 62: 1442-50, 2021.